Navigation Links
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Date:1/12/2009

under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and E
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
3. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
4. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
5. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
8. Pharmasset Joins Russell 3000 Index
9. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
10. Pharmasset Selected to Join the NASDAQ Biotechnology Index
11. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... -- Pioneer Surgical Technology, Inc. is pleased to announce that ... feasibility study patients was presented at the recent 10th annual meeting of ... New Orleans by Domagoj Coric , M.D., Chief, Department of ... , , ...
... , June 1 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: YONG ... brand plant and animal nutrient products in, China , today announced that ... Company, in,cooperation with the central government of Inner Mongolia Autonomous Region,hosted the ... , , ...
... The ... its curriculum. The online drug safety training courses from BioSoteria will form the ... students, postdoctoral fellows, and residents via the University of Maryland’s Blackboard system. ... Baltimore, MD and ...
Cached Biology Technology:Two-Year Follow up Data of NuBacĀ® IDE Feasibility Study Was Presented at SAS Meeting 2Yongye International Hosts Official NASDAQ Visit to Inner Mongolia 2Yongye International Hosts Official NASDAQ Visit to Inner Mongolia 3Yongye International Hosts Official NASDAQ Visit to Inner Mongolia 4University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 2University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 3University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 4
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... infection is highly complex, research to understand how people ... occur in simpler organisms. Zebrafish are becoming an important ... maintained and manipulated and many fundamental processes between zebrafish ... embryo is highly amenable to drug screening assays. The ...
... Medical Center scientists have won prestigious National Institutes of ... Reya, Ph.D., an associate professor of pharmacology and cancer ... Michel Bagnat, Ph.D., assistant professor of cell biology, won ... of the 18 Pioneer Awards provides $2.5 million in ...
... BOSTON (9-24-09) -- The National Institutes of Health ... team led by Boston University biomedical engineer Bela Suki ... cell function, with the goal of understanding the possible ... diseases, metabolic disorders, aging and cancer. NIH today ...
Cached Biology News:Fish fend off invading germs with an initial response similar to the one found in people 2Duke biomedical scientists win 2 highly prized NIH Director's Awards 2Boston University engineer to use $2.5 million NIH grant to cells' reaction to physical force 2
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
acridine orange 10-nonyl bromide (nonyl acridine orange)...
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
Biology Products: